Advertisement
Organisation › Details
Novome Biotechnologies Inc.
Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. *
Start | 2016-01-01 established (s-off) | |
Predecessor | Stanford University | |
Industry | Genetically Engineered Microbial Medicines (GEMMs) | |
Industry 2 | genome editing (gene editing) | |
Person | Wise, Blake (Novome Biotechnologies 202001– CEO before Achaogen + Genentech) | |
Region | South San Francisco, CA | |
Country | United States (USA) | |
Street | 279 E. Grand Ave. Suite 420 | |
City | 94080 South San Francisco, CA | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Novome Biotechnologies, Inc.. (1/7/20). "Press Release: Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer". South San Francisco, CA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Novome Biotechnologies Inc.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top